


# Stabilis

Na Ca  
K Mg



## Potassium phosphate
































Noms commerciaux

Addiphos	Danemark, Irlande, Pologne, Suède
Bifosfato de potasio	Chili
Deplecat	Mexique
Fosfato de potasio	Espagne, Pérou, Vénézuéla
K Fosfoferil	Finlande
Kaliumphosphat	Autriche, Pologne
Phosphate de potassium	Canada, France, Suisse
Potassio fosfato	Italie
Potassium phosphate	Arabie Saoudite, Canada, Grèce, Irlande



### Compatibilités

				
		Potassium phosphate : 0.12 mmol/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Potassium phosphate : 3 mmol/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Potassium phosphate : 4.4 mmol/ml Caffeine : 10 mg/ml		3964
		Potassium phosphate Calcium chloride		3621
		Potassium phosphate Calcium glucoheptonate		3621
		Potassium phosphate Calcium gluconate		3644
		Potassium phosphate Calcium gluconate		3621
		Potassium phosphate : 0,5 mmol/ml Caspofungin acetate : 0,7 mg/ml		2247
		Potassium phosphate : 0,3 mmol/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Potassium phosphate : 3 mmol/ml	RL	4603
		Potassium phosphate : 0,5 mmol/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Potassium phosphate : 0,5 mmol/ml Ceftaroline fosamil : 2,22 mg/ml		3249

		Potassium phosphate : 0.5 mmol/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
		Potassium phosphate : 0.5 mmol/ml Ceftobiprole medocartil sodium : 2 mg/ml		2269
		Potassium phosphate : 0.3 mmol/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Potassium phosphate : 0.00012 mmol/ml		3948
		Potassium phosphate Ceftobiprole medocartil sodium		4650
		Potassium phosphate : 3 mmol/ml Ciprofloxacin lactate : 2 mg/ml		261
		Potassium phosphate : 0.015 mmol/ml Diltiazem hydrochloride : 5 mg/ml		198
		Potassium phosphate : 0.44 mmol/ml Enalaprilate : 0.05 mg/ml		1315
		Potassium phosphate : 3 mmol/ml		1415
		Potassium phosphate : 3 mmol/ml Cloxacillin sodium : 100 mg/ml		3012
		Potassium phosphate Dobutamine hydrochloride : 0.19 mg/ml		1221
		Potassium phosphate : 0.5 mmol/ml Doripenem : 5 mg/ml		2262
		Potassium phosphate : 0,44 mmol/ml Esmolol hydrochloride : 10 mg/ml		384
		Potassium phosphate : 0.00012 mmol/ml		3948
		Potassium phosphate Folate calcium		3621
		Potassium phosphate : 0.3 mmol/ml Fosfomycin : 30 mg/ml		4055
		Potassium phosphate : 3 mmol/ml		301
		Potassium phosphate Furosemide : 1 & 10 mg/ml		3781
		Potassium phosphate Heparin sodium		3781
		Potassium phosphate : 0,4 mmol/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Potassium phosphate Insulin		3781
		Potassium phosphate : 0.3 mmol/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Potassium phosphate : 4 mmol/ml Ketamine hydrochloride : 50 mg/ml		2109
		Potassium phosphate : 0.44 mmol/ml Labetalol hydrochloride : 1 mg/ml		386
		Potassium phosphate : 3 mmol/ml Lansoprazole : 0.55 mg/ml		1625
		Potassium phosphate Levofolate calcium		3621
		Potassium phosphate Magnesium sulfate		3838

		Potassium phosphate Magnesium sulfate		3781
		Potassium phosphate Magnesium sulfate		3621
		Potassium phosphate : 3 mmol/ml Magnesium sulfate : 500 mg/ml		4389
		Potassium phosphate : 3 mmol/ml Meropenem : 50 mg/ml		4319
		Potassium phosphate : 0.5 mmol/ml Micafungin : 1.5 mg/ml		2108
		Potassium phosphate Midazolam hydrochloride		3781
		Potassium phosphate : 3 mmol/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Potassium phosphate : 0.44 mmol/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Potassium phosphate Pantoprazole sodium		2090
		Potassium phosphate : 0.3 mmol/ml Plazomicin sulfate : 24 mg/ml		4145
		Potassium phosphate Propofol		3781
		Potassium phosphate : 1 mmol/ml Remifentanil hydrochloride : 120 µg/ml		3176
		Potassium phosphate Remifentanil hydrochloride		3781
		Potassium phosphate : 1 mmol/ml Remifentanil hydrochloride : 120 µg/ml		3294
		Potassium phosphate : 3 mmol/ml Salbutamol sulfate : 1 mg/ml		3216
		Potassium phosphate : 3 mmol/ml Sodium bicarbonate : 84 mg/ml		4389
		Potassium phosphate : 1 mmol/ml Sufentanil citrate : 0.005 mg/ml		3294
		Potassium phosphate : 0.3 mmol/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Potassium phosphate : 3 mmol/ml Thiopental sodium : 25 mg/ml		3767
		Potassium phosphate : 0.088 mmol/ml Verapamil hydrochloride : 0.08 mg/ml		1057



## Voie d'administration





## Bibliographie

	Type	Source
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
261	Revue	Percy LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 715-716.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1221	Revue	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.

2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3294	Revue	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3621	Laboratoire	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015

3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416?424.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Sch?rer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	C?té K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilit? physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosi-mendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barth?lémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021



# Dictionnaire

	électrolyte		Injectable
	Noms commerciaux		Compatibilités
	Molécule		Solvant
	Bibliographie		Précipitation immédiate
	Incompatible		Glucose 5%
	Compatible		Précipitation en 4 heures
	Aucun		Incompatibilité non précisée
	Chlorure de sodium 0,9%		NaCl 0,9% ou glucose 5%
RL	Ringer lactate		Turbidité immédiate
	Nutrition parentérale (mélange binaire)		Instabilité de l'émulsion immédiate
	Nutrition parentérale (mélange ternaire)		Incompatibilité subvisuelle
	Eau pour préparation injectable		Précipitation en 1 heure
	Turbidité en 1 heure		Dégagement gazeux
	Voie d'administration		Perfusion continue
	Bibliographie		Dictionnaire